Objective: Tyrosine kinase inhibitors (TKIs) are widely used drugs which have high availability in reducing
the activity of BCR-ABL1 tyrosine kinase, therefore they play an indispensable role in the treatment of Chronic myeloid
leukemia (CML). Imatinib, dasatinib and nilotinib have been proved to have absolute bioavailability and stable
blood concentration in humans. TKIs pharmacokinetics has close relationships with the clinical response and clinical
treatment of CML.
Method: We conducted a systematic PubMed search to look for studies relating to TKIs pharmacokinetics with proper
inclusion/exclusion criteria. After looking through a large number of references, we investigated that different generations
of TKIs could be influenced by many factors. We chose some typical factors which were closely linked to the
common treatment of CML. These factors contain daily dose, diet, individual variability, drug-drug interaction, drugs
resistance and drug withdrawal.
Results: By summarizing up these influence factors, we hope it can make a contribution to clinical therapy. Above all, the
relationship between influence factors and the clinical therapeutic effect is the key point that our research pays attention to.
Conclusion: This review highlights certain influence factors of TKIs clinical pharmacokinetics.